The purpose of this transmittal is to outline the policy change that the District Medicaid program will implement effective March 1, 2021 for orally administered Direct Acting Antivirals (DAAs) used in the current treatment of chronic Hepatitis C infection for Medicaid [Fee for Service (FFS) and managed care (MCO)] enrolled beneficiaries.